Drug research

Acellular Tissue Engineered Vessel (ATEV)

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as Human Acellular Vessel (HAV)

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring HemodialysisNCT05908084	HUMA	Phase 3	Active not recruiting	2027-06Estimated
Humacyte Acellular Tissue Engineered Vessel (ATEV) in Patients With Vascular TraumaNCT03005418	HUMA	Phase 2, Phase 3	Completed	2023-09-19Actual

HUMAActive not recruitingPrimary completion: 2027-06 · Estimated

Trial details

HUMACompletedPrimary completion: 2023-09-19 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.